Vol. 3 No. 2 (2023)
Reimbursement Reviews

Edaravone Oral Suspension (Radicava)

Published February 24, 2023

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses edaravone oral suspension (Radicava), 105 mg per 5 mL of suspension.
  • Indication: Treatment of patients with amyotrophic lateral sclerosis.